Literature DB >> 15237383

Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation.

Heikki Makisalo1, Anu Koivusalo, Anne Vakkuri, Krister Hockerstedt.   

Abstract

Liver transplantation (LT) may be indicated in cirrhotic patients with underlying pulmonary artery hypertension. However, severe pulmonary artery hypertension with mean pulmonary artery pressure (mPAP) above 50 mmHg has even been considered a contraindication to LT. We present a cirrhotic patient with an mPAP of 56 mmHg measured using right heart catheterization (RHC) and with severely compromised physical capacity. She was first treated with sildenafil (Viagra), a potent novel vasodilator, and successfully transplanted later. The mPAP decreased with sildenafil to the level of 28-31 mmHg and her general condition improved markedly. An LT using piggyback technique was performed 16 weeks later. Despite 2 reoperations for bleeding, the outcome has been excellent. In conclusion, treatment of severe portopulmonary hypertension (PHT) with sildenafil is effective. If a decrease in mPAP is achieved with sildenafil, it may improve the result of LT, even though no evidence of reversibility of PPHTN exists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237383     DOI: 10.1002/lt.20153

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

1.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 2.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

Review 4.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

6.  Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.

Authors:  Ying-Wen Wang; Han-Chieh Lin; Ying-Ying Yang; Ming-Chih Hou; Shou-Dong Lee
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

7.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 8.  Management of portopulmonary hypertension: new perspectives.

Authors:  Luigi Mancuso; Francesca Scordato; Michela Pieri; Eliana Valerio; Andrea Mancuso
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Intraoperative pulmonary hypertension occurred in an asymptomatic patient with pre-existent liver cirrhotic and portal hypertension.

Authors:  Ling Lu; Feng Zhang; Xiang-Cheng Li; Guo-Qiang Li; Chuan-Yong Zhang; Xue-Hao Wang
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

10.  Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation.

Authors:  Anna R Hemnes; Ivan M Robbins
Journal:  Liver Transpl       Date:  2009-01       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.